Therapies

Corporate Sponsors

Champion Sponsor

Emerging Sponsor

Supporting Sponsor

Premier Sponsor

Champion Sponsor

Champion Sponsor

Agios Pharmaceuticals

Supporting Sponsor

Supporting Sponsor

Champion Sponsor

Supporting Sponsor

Champion Sponsor

Coherus Biosciences

Champion Sponsor

Champion Sponsor

Champion Sponsor

Global Blood Therapeutics

Emerging Sponsor

Emerging Sponsor

Meijer Specialty Pharmacy

Emerging Sponsor

Dova Pharmaceuticals

Champion Sponsor

Premier Plus Sponsor

Supporting Sponsor

Advanced Accelerator Applications

Champion Sponsor

Karyopharm Therapeutics

Champion Sponsor

Supporting Sponsor

Supporting Sponsor

Champion Sponsor

Champion Sponsor

Premier Sponsor

Supporting Sponsor

Premier Sponsor

Supporting Sponsor

Premier Sponsor

Premier Sponsor

Premier Plus Sponsor

Premier Plus Sponsor

Premier Plus Sponsor

Champion Sponsor

Champion Sponsor

Premier Sponsor

Seattle Genetics

Premier Sponsor

Supporting Sponsor

Premier Sponsor

Premier Plus Sponsor

Champion Sponsor

Champion Sponsor

Premier Plus Sponsor

Premier Plus Sponsor

Champion Sponsor

Premier Sponsor

Supporting Sponsor

Champion Sponsor

view all sponsors

Advocacy

MSHO continuously contacts legislators, provides comments to policy makers and collaborates with payers on issues of concern to those delivering care to cancer patients.

Education

It is important that our members are aware of meetings, web casts, and other educational opportunities specifically designed to address the complexities of cancer care.

Research

MSHO is committed to furthering the advancement of cancer care by supporting the many organizations that provide cancer clinical trials to Michigan’s cancer patients.

Drug Updates

IBRANCE® (palbociclib) is transitioning from capsules to tablets

Important safety information and full prescribing information for capsules

ADAKVEO® (crizanlizumab-tmca) C-Code Assignment Effective 4/1/20

Drug Repository Programs Address High Costs, Access and Waste Issues When Appropriately Implemented

FDA Gets Ready for Changes to Biologics Regulation

As Patents Expire, Oncology Biosimilars Poised to Expand, Authors Say

Pfizer Brings Three New Biosimilars to U.S. Patients at Substantial Discounts

Rare diseases top another strong year for novel drug approvals

U.S. Officials Will Let Novartis Pay Expenses for Some Kymriah Patients Who Must Travel for Treatment

U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Non-Small Cell Lung Cancer